On 13 October 2024, Enterosgel was presented at the UEG (United European Gastroenterology) Gastroenterology Congress in Vienna. Our organization has traditionally participated in the UEG congress for the third consecutive year and has always enjoyed great interest from experts. Enterosgel, which has been on the market for more than 30 years, has been proven to help diarrhoea of various origins. We are particularly pleased that in the latest studies and modern methods of treating functional disorders associated with diseases of civilization, such as IBS-D, Enterosgel continues to prove its effectiveness and is increasingly recognized and used by leading experts in gastroenterology worldwide.
Here are highlights of the UEG's discussion of Enterosgel's role in innovative therapies for gastrointestinal disorders:
Highlight 1: Jan Tack's presentation on pharmacological options for the treatment of irritable bowel syndrome.
The first lecture in the main program, "How to choose the best pharmacological options for our IBS patients?" Professor Jan Tack from Belgium, attracted a lot of attention. Professor Tack, known as one of the world's leading neurogastroenterologists, mentioned Enterosgel during his presentation and highlighted its efficacy in IBS patients. Following his remarks, many attendees sought further information about Enterosgel at our booth, underscoring the interest that his endorsement generated. Although detailed findings from the talk are not yet available, feedback from attendees suggests Enterosgel's growing reputation as a trusted therapy for IBS symptoms.
Highlight 2: Peter Whorwell's lecture on the treatment of diarrhoea in irritable bowel syndrome
Later in the day, Professor Peter Whorwell from the United Kingdom gave a lecture entitled "Treatment of Diarrhoea in IBS" as part of the main programme. His presentation included a slide highlighting Enterosgel as a key therapeutic option. Professor Whorwell highlighted two distinct advantages of Enterosgel:
- Unlike many other treatments for diarrhea, Enterosgel also relieves abdominal pain, a common and challenging symptom in IBS.
- Patients value Enterosgel for its ability to safely address feelings of toxicity and balance gut health, which is consistent with their intuitive needs.
- The presentation placed Enterosgel alongside other important therapies such as loperamide, fiber and newer medications, cementing its place in the treatment of IBS.
Highlight 3: Poster presentation on enterosorbents in LARS syndrome
In the poster session, Dr. Ilario Froehner Jr. from Brazil presented his own clinical data on the use of Enterosgel to manage fecal incontinence in patients with low anterior resection syndrome (LARS). His presentation, entitled "Low Anterior Resection Syndrome - A Never-Ending Challenge. What is the Role of Enterosorbents?" shared promising preliminary results from a study involving 15 patients. Key findings included the following:
- Enterosgel was administered in doses of 5 g three times daily, with water intake adjusted for stool consistency. Patients consumed 250-300 ml of water for hard stools, 200 ml of water for normal stools and 50 ml of water for loose stools.
Initial results suggest that Enterosgel may be a suitable product for improving stool consistency and alleviating symptoms of fecal incontinence in patients with LARS.
Although these data are preliminary and have not yet been reviewed, they highlight the potential of Enterosgel in addressing complex gastrointestinal problems beyond IBS.
Growing recognition for Enterosgel
Enterosgel continues to demonstrate its value as an innovative therapeutic solution, from its efficacy in managing IBS symptoms to its potential role in LARS syndrome.
We participate in many professional conferences and enjoy contributing to cutting-edge clinical research that helps physicians make every patient's life happier, more comfortable and healthier. Thank you to everyone who visited our booth and engaged in meaningful discussions about this groundbreaking enterosorbent.